News articles about Abcam (LON:ABC) have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abcam earned a media sentiment score of -3.92 on their scale. InfoTrie also assigned news headlines about the company an news buzz score of 3 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock’s share price in the near future.
Shares of ABC opened at GBX 1,151 ($15.04) on Tuesday. The stock has a market cap of $2.37 billion and a price-to-earnings ratio of 52.80. Abcam has a 12 month low of GBX 1,006 ($13.15) and a 12 month high of GBX 1,523 ($19.90). The company has a 50-day moving average price of GBX 1,152.82 and a two-hundred day moving average price of GBX 1,283.50.
The company also recently announced a dividend, which will be paid on Friday, November 29th. Stockholders of record on Thursday, November 7th will be paid a GBX 8.58 ($0.11) dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a dividend yield of 0.74%. This is a boost from Abcam’s previous dividend of $3.55. Abcam’s payout ratio is 0.55%.
ABC has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on shares of Abcam from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) and set a “neutral” rating for the company in a research note on Monday, September 16th. Berenberg Bank restated a “buy” rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a research note on Monday, September 9th. Peel Hunt restated an “add” rating on shares of Abcam in a research note on Monday, October 7th. Finally, Liberum Capital initiated coverage on shares of Abcam in a research note on Monday, September 30th. They set a “hold” rating and a GBX 1,230 ($16.07) price target for the company. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 1,266.80 ($16.55).
In other news, insider Jonathan Simon Milner sold 170,000 shares of Abcam stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of GBX 1,147 ($14.99), for a total value of £1,949,900 ($2,547,889.72). Also, insider Gavin Wood bought 2,500 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was purchased at an average price of GBX 1,157 ($15.12) per share, with a total value of £28,925 ($37,795.64).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Story: The role of implied volatility with call option volume
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.